Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · IEX Real-Time Price · USD
3.010
-0.120 (-3.83%)
At close: May 17, 2024, 4:00 PM
3.070
+0.060 (1.99%)
After-hours: May 17, 2024, 4:34 PM EDT
Century Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for IPSC stock have an average target of 13.67, with a low estimate of 5.00 and a high estimate of 24. The average target predicts an increase of 354.15% from the current stock price of 3.01.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IPSC stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +265.45% | May 10, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $10 → $9 | Buy | Reiterates | $10 → $9 | +199.00% | Apr 12, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 → $24 | Strong Buy | Maintains | $22 → $24 | +697.34% | Mar 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +331.89% | Mar 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +331.89% | Dec 7, 2023 |
Financial Forecast
Revenue This Year
6.13M
from 2.24M
Increased by 174.41%
Revenue Next Year
20.17M
from 6.13M
Increased by 228.89%
EPS This Year
-2.15
from -2.30
EPS Next Year
-2.01
from -2.15
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 32.5M | 52.5M | 43.8M | 74.1M | 121.4M |
| Avg | 6.1M | 20.2M | 15.5M | 36.0M | 91.1M |
| Low | n/a | 392,000 | n/a | n/a | 61.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,355.2% | 756.0% | 117.2% | 376.8% | 237.2% |
| Avg | 174.4% | 228.9% | -22.9% | 131.6% | 153.0% |
| Low | - | -93.6% | - | - | 71.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.84 | -1.49 | -1.47 |
| Avg | -2.15 | -2.01 | -1.97 |
| Low | -2.29 | -2.81 | -2.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.